Last reviewed · How we verify
VINFLUNINE DITARTRATE
VINFLUNINE DITARTRATE is a drug. It is currently FDA-approved (first approved 2009).
Vinflunine ditarrate is a small molecule inhibitor that targets tubulin. It is classified as a tubulin inhibitor, which is a type of drug that works by inhibiting the function of tubulin.
At a glance
| Generic name | VINFLUNINE DITARTRATE |
|---|---|
| Modality | Small molecule |
| Phase | FDA-approved |
| First approval | 2009 |
Approved indications
Common side effects
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- VINFLUNINE DITARTRATE CI brief — competitive landscape report
- VINFLUNINE DITARTRATE updates RSS · CI watch RSS
Frequently asked questions about VINFLUNINE DITARTRATE
What is VINFLUNINE DITARTRATE?
VINFLUNINE DITARTRATE is a Small molecule drug.
When was VINFLUNINE DITARTRATE approved?
VINFLUNINE DITARTRATE was first approved on 2009.
What development phase is VINFLUNINE DITARTRATE in?
VINFLUNINE DITARTRATE is FDA-approved (marketed).
Related
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing